Health Care Select Sector

S&P 500

The Balanced Allocator

Comparable Companies - CVS

The insider trading data shows 5 discretionary purchases and 8 discretionary sales in the last 12 months. The latest short interest is 1.3% of float with a days‑to‑cover ratio of 1.8 days as of 2026-02-13. The primary institutional holders are BlackRock, Inc. (9.4% stake) and Vanguard Group Inc. (9.4% stake).

DIRECTOR

EVP AND PRESIDENT, AETNA

EVP AND CHIEF PEOPLE OFFICER

SVP, CONT & CHIEF ACCT OFFICER

Disclosure of beneficial ownership of 105,292,588 shares representing 8.3% of the class, filed under Item 4 of Schedule 13G/A.

Disclosure of beneficial ownership of 68,785,990 shares representing 5.5% of the class, filed under Item 4 of Schedule 13G.

Disclosure of beneficial ownership of 89,218,268 shares representing 7.1% of the class, filed under Item 4 of Schedule 13G/A.

Elected as Chair of the Board effective January 1, 2026, consolidating the CEO and Chair roles following his appointment as CEO in October 2024.

President, Chief Executive Officer and Chair of the Board

Appointed as CFO to succeed Thomas Cowhey; previously served as CFO of United Parcel Service (UPS).

Executive VP and Chief Financial Officer

Stepped down as CFO in May 2025 to serve as a strategic advisor before becoming CFO of athenahealth in June 2025.

Former EVP and Chief Financial Officer

Appointed to the board following productive discussions with Glenview Capital Management to drive operational performance.

Independent Director

Newly created role to lead clinical operations and health outcome improvements across the enterprise.

Executive VP and Chief Medical Officer

Stepped down as CEO in October 2024 amid financial challenges in the Aetna insurance segment.

Former President and Chief Executive Officer

J. David Joyner

Brian Newman

Prem S. Shah

Michael F. Mahoney

Larry M. Robbins

Roger N. Farah

J. David Joyner represents a return to operational fundamentals for CVS Health. His extensive 37-year history within the organization, particularly his success in the high-margin PBM business, provides him with the 'provenance' to navigate the current regulatory scrutiny of PBMs while simultaneously stabilizing the Aetna insurance segment. His elevation to Board Chair in 2026 signals absolute board confidence in his turnaround strategy, which has already delivered record revenues and improved earnings guidance for 2026.

Brian Newman brings external financial rigor to CVS Health, a necessary counterbalance to the company's internal-heavy leadership. His experience at UPS and PepsiCo in managing complex, low-margin logistics and consumer businesses is directly applicable to CVS's retail and PBM operations. His primary value lies in restoring investor trust through conservative, achievable guidance and aggressive cost management.

Fernando Aguirre

Jeffrey R. Balser

C. David Brown II

Alecia A. DeCoudreaux

Anne M. Finucane

J. Scott Kirby

Leslie V. Norwalk

Guy P. Sansone

Douglas H. Shulman

Retail pharmacy and wholesale pharmaceutical distribution with a global footprint.

Global healthcare services and products company providing pharmaceutical distribution and medical product solutions.

Pharmaceutical distribution and specialty solutions.

Global medical products and distribution.

Other operating segments including at-home solutions.

Health insurance and managed care provider offering comprehensive health benefit programs.

Hospital and healthcare services operator with a network of facilities across the United States.

Principal office in Woonsocket, Rhode Island (approximately 1 million sq ft owned); Health Care Benefits headquarters in Hartford, Connecticut (approximately 1.7 million sq ft owned); roughly 9,000 retail locations (about 71.3 million sq ft net selling space, 4% owned) and 1,000+ MinuteClinic locations; owned distribution centers and leased distribution facilities totaling about 10 million sq ft; 246 primary-care centers across 27 states (approximately 2.2 million sq ft); additional office, call-center and technology spaces leased or owned throughout the United States and Ireland.

CVS Health's FY2025 delivered 7.8% revenue growth to $402.1B from prescription volume and Rite Aid integration, but operating income collapsed 45% to $4.7B via $5.7B goodwill impairment and SG&A rise, with robust $10.6B NCFO (5.9x net income) offset by 106% Debt/Equity and negative tangible book at -$35.8B; the new Joyner-led team shows adequate internal execution and activist board refresh as strengths, but weak capital discipline via ongoing returns amid 15.3x leverage and legacy incentives render it mismatched for rapid turnaround, risking equity value without survival-mode shifts.

The company is subject to various environmental, health, and safety regulations at federal, state, and local levels, including those governing hazardous substances, contaminated sites, and safe working conditions. Non-compliance could result in fines or sanctions.

The company employed over 300,000 colleagues as of December 31, 2025, with approximately 73% full-time, primarily in the U.S.

The company faces risks related to product liability, recalls, professional liability, and data privacy. It has compliance programs to prevent and detect prohibited practices, but incidents could lead to reputational harm, litigation, and regulatory actions.

The company engages in community programs addressing health outcomes, food insecurity, and workforce training. It also focuses on packaging innovation to reduce waste, but detailed responsible sourcing disclosures are not prominent.

Revenue grew 7.8% to $402.1 B in FY 2025, but operating margin fell to 1.2% and net margin to 0.4% after a $5.7 B goodwill impairment and SG&A rising to $44.98 B.

The 10‑K MD&A disclosed that 77% of FY 2025 CapEx was allocated to technology, digital platforms, and strategic initiatives, with the remainder supporting store and fulfillment infrastructure (P14 innovation dossier). Management reiterated a $20 B ten‑year investment commitment focused on AI, cloud, and enterprise connectivity.

The MD&A disclosed a $5.7 B goodwill impairment in Health Services, $607 M store‑right‑of‑use impairment, $10 M office‑real‑estate optimization charge, and $269 M non‑core asset impairments in FY 2025, indicating recurring write‑downs. No Critical Audit Matter related to impairments was identified by the auditor.

The 353% incremental ROIC stems largely from one‑time goodwill impairment and other write‑downs rather than genuine value‑creating investments. Capital invested in technology (77% of CapEx) and the $20 B ten‑year reinvestment plan have not yet translated into higher operating returns, as operating margin declined.

Glenview Capital Management (Larry Robbins)

Sachem Head Capital Management

Back-up revolving credit facilities (three $2.5 B unsecured facilities)

Senior notes issued August 15 2025 (aggregate $4.0 B: $750 M 5.0% due 2032, $1.5 B 5.45% due 2035, $1.25 B 6.2% due 2055, $500 M 6.25% due 2065)

Junior subordinated notes issued December 10 2024 (aggregate $3.0 B: $2.25 B 7.0% Series A due 2055, $750 M 6.75% Series B due 2054)

Term loan agreement (364-day $3.0 B) - terminated May 9 2024

EV/EBITDA

P/FCF

Thomas F. Cowhey

Heidi B. Capozzi

Jean-Pier Millon

Mary L. Schapiro

All directors, executive officers and former executive officers as a group (24 persons)

Samrat S. Khichi

Steven H. Nelson

CVS Health maintains stock ownership guidelines for all directors and officers serving on the ELT and all corporate-level executive vice presidents and senior vice presidents. Compliance must be achieved within five years. Shares counted include shares owned outright, unvested RSUs, shares in Deferred Stock Compensation Plan, and shares purchased through Employee Stock Purchase Plan. Unexercised stock options and unearned PSUs do not count.

Elect the 13 director nominees named in this proxy statement

Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2025

Say on pay, an advisory vote to approve the Company's executive compensation

Stockholder proposal for reducing the threshold for our stockholder right to act by written consent. Proposal from John Chevedden to enable 10% of shares to request a record date to initiate written consent.

President and Chief Executive Officer

EVP and Chief Financial Officer

Executive VP & Chief People Officer

Tilak Mandadi

Executive VP, Chief Experience & Technology Officer

Executive VP & Group President

Karen S. Lynch

CVS Health Corporation operates as a diversified health services and retail company with four reportable segments: Health Care Benefits (provides health insurance products, Medicare Advantage, Medicaid and other benefit plans), Health Services (operates a pharmacy benefit manager, specialty and mail-order pharmacy services, and a network of walk-in medical clinics), Pharmacy & Consumer Wellness (runs approximately 9,000 CVS Pharmacy retail locations, sells prescription drugs, over-the-counter health and wellness products, and offers pharmacy-related services such as vaccinations), and Corporate/Other (includes corporate overhead, management of non-core assets and legacy insurance products). The company has grown through organic expansion and acquisitions, most recently integrating Rite Aid prescription files, Signify Health and Oak Street Health.

Provides health insurance products, including Medicare Advantage, Medicaid, employer-sponsored plans and other benefit offerings; generates premium revenue and assumes medical benefit risk.

Operates the pharmacy benefit manager, specialty and mail-order pharmacy fulfillment, and a network of walk-in medical clinics; earns PBM fees, drug rebates and service fees.

Runs CVS retail pharmacy locations, sells prescription drugs, over-the-counter health and wellness products, and provides ancillary services such as vaccinations and infusion therapy.

Includes corporate overhead, management of non-core insurance products, restructuring activities and other administrative functions.

Held base revenue forecast, base terminal multiple 14.0x, and WACC 10.0% constant to justify current price of 78.69.

Balance Sheet - Supplemental

Balance Sheet

Cash Flow Statement - Supplemental

Cash Flow Statement

Income Statement - Supplemental

Income Statement

Ratios

Valuation

Historical Ratios & Multiples - CVS

The industry is facing a 'destructive' phase of the capital cycle. While an aging population increases demand, regulatory rate caps and rising medical utilization are compressing margins across the payer space. CVS is underperforming the sector, with a 3-year alpha of -37.15% versus the market.

CVS is at a critical juncture following the appointment of J. David Joyner and the entry of Glenview Capital, with the market awaiting proof that the $2B cost-savings plan can offset structural headwinds in Medicare Advantage.

Aetna Medical Benefit Ratio (MBR) falling below 91% in Q3 2026. This would validate the margin-recovery narrative and suggest that pricing actions are finally offsetting utilization trends.

Successful divestiture of non-core assets (e.g., Oak Street Health or Signify Health). Selling these assets at a premium would provide a crucial bridge to safety and allow for debt paydown.

Existential Liquidity and Solvency Risk. The company faces a 'race against time' to restore operating income before its $15.7B in 2026 debt maturities become unrefinancable at sustainable rates.

Regulatory Impairment of PBM Profitability. An FTC lawsuit regarding insulin pricing and potential federal legislation could permanently cap PBM margins.

The governance environment is currently a 'Battleground.' We outline the Governance Outcome Tree: 1. Status Quo: Joyner executes the $2B plan, leading to modest recovery (Base Case); 2. Compromise: Glenview gains more influence, potentially forcing a spin-off of Aetna or the PBM; 3. Reset: Continued misses lead to a full board overhaul or a forced strategic sale. Given that insiders sold $254.6M in stock over the...

The current Property, Plant & Equipment base for CVS Health as of the December 31, 2025 balance sheet consists of a gross investment of $37,827,000,000, which nets to $13,083,000,000 after accumulated depreciation, excluding Right-of-Use (ROU) assets. The core tangible footprint includes a 1 million square foot owned headquarters in Woonsocket, RI, a 1.7 million square foot owned complex in Hartford, CT (Aetna), and a vast network of owned and leased retail pharmacies, mail-order dispensing facilities, and Oak Street Health clinics. Per the P7 Transcript Analysis, the asset base has recently evolved through the integration of Rite Aid pharmacy assets (9 million patients) and the completion of a 900-store closure program, shifting the footprint toward higher-utilization health service centers and away from underperforming retail nodes.

Rite Aid Bankruptcy Liquidation: Sale of prescription files and select store assets to CVS and Walgreens. While prescription files (intangibles) fetched high premiums, the physical fixtures and equipment (FF&E) typically recovered only 5% to 12% of original cost in orderly liquidation auctions.

Walgreens Boots Alliance (WBA) Store Optimization: As part of its plan to close 1,200 stores, WBA has engaged in sale-leaseback and outright sales of owned retail properties. Prime retail pharmacy locations in high-traffic urban corridors have maintained 75% to 85% of appraised market value even in accelerated sale scenarios.

Cash & Equivalents

Accounts Receivable

CVS's inventory is its most liquid tangible asset. With a book value of $19,246,000,000 and a turnover rate of 19x, the stock is highly current. The valuation logic hinges on the fact that pharmacy inventory is not 'fashion' or 'seasonal' but essential medicine with established buy-back protocols from major wholesalers. A conservative 70% recovery rate is justified by the high proportion of prescription drugs in the mix, which maintains value far better than general retail merchandise.

Inventory

Short-Term Inv.

Other Current Assets

Net PP&E

Intangibles

Long-Term Inv.

Other Non-Current

Accounts Payable

Current Debt

Other Current Liabilities

Non-Current Debt

Tax Liabilities (Deferred)

Other Non-Current Liabilities

Capital World Investors reports 5.5% passive stake in CVS Health common stock

CVS Health announces CFO transition and new Chief Medical Officer appointments

Market/Sector Move -5.70%

CVS Health reports Q4 and full-year 2024 results with revenue growth but segment challenges

CVS Health announces early results of tender offer for senior notes

CVS Health issues $3 billion in new subordinated notes

CVS Health reports Q3 2024 results with revenue growth but significant segment challenges

CVS Health announces CEO transition and preliminary Q3 2024 results

CVS Health reports Q1 2024 results and revises full-year guidance

CVS Health reports partial termination of Blue Shield of California contract

CVS Health reports impact of Medicare Advantage star rating decline

CVS Health reported strong Q2 2022 results with revenue growth across all segments and raised full-year guidance.

CVS Health reported strong Q4 and full-year 2021 results, confirming 2022 guidance.

CVS Health reports strong third quarter 2021 results with revenue growth and raised guidance

CVS Health price target lowered to $90 from $91 at Argus

CVS Health price target raised to $91 from $87 at Bernstein

BofA Securities Reiterates Buy Rating on CVS Health (CVS)

CVS Health price target raised to $93 from $81 at RBC Capital

CVS Health price target raised to $96 from $79 at UBS

CVS Health initiated with a Buy at Goldman Sachs

CVS Health price target raised to $88 from $76 at Mizuho

CVS Health price target raised to $103 from $84 at Wells Fargo

CVS Health price target raised to $87 from $86 at Bernstein

CVS Health price target raised to $86 from $77 at Bernstein

Situation: Current price is $80.57 versus fair value $65.36 (-18.9% expected return), and valuation confidence is partial. Debate: Bull case depends on Aetna Medical Benefit Ratio (MBR) falling below 91% in Q3 2026. Bear case centers on Existential Liquidity and Solvency Risk. Conclusion: Recommendation is Sell with no position, pending a materially better risk/reward setup.

Executive Summary

The primary value driver is a desperate attempt to restore margins through a $2B cost-savings program and Aetna repricing. However, the catalyst for further downside is the high likelihood of continued Medicare Advantage utilization spikes and Federal Trade Commission (FTC) intervention in PBM pricing. With negative tangible book value, there is no asset-based floor to protect equity holders if the turnaround falters.<ul><li>Driver: Structural margin erosion and excessive leverage</li><li>Catalyst: Failure to meet Aetna margin recovery targets or adverse PBM regulatory resets</li><li>Protection: None</li></ul>Our variant perception is that the market has priced this company for a successful operational recovery, ignoring the extreme financial distress signaled by a 1.7x interest coverage ratio and a $5.7B goodwill impairment. While some view CVS as a deep-value play at a 9.4x forward P/E, our analysis of the liquidity runway and the $79.95B debt wall suggests the current price does not adequately reflect the risk of a zero-equity outcome in a failed restructuring.This is therefore not a bet on an operational turnaround by current management, but a special situation, asset-based investment with a clearly defined catalyst path that currently points toward significant overvaluation.

Core Investment Rationale

CVS Health operates as a vertically integrated healthcare giant across three primary segments: Health Care Benefits (Aetna), Health Services (Caremark PBM), and Pharmacy & Consumer Wellness (Retail). The strategy relies on enterprise connectivity to lower costs, yet the model is under siege. Revenue grew 7.8% YoY to $402.1B in FY2025, but this growth was largely driven by low-margin Rite Aid prescription file integrations rather than organic high-value expansion. The company is currently executing a $2B cost-reduction plan and closing 900 stores to stem the bleeding in its retail footprint.Core assets include the Aetna insurance platform serving millions of members, the Caremark PBM which processes over 2 billion claims annually, and a retail network of approximately 9,000 locations. However, the quality of these assets is deteriorating. The company recorded a $5.7B goodwill impairment in its Health Services segment in 2025, and its tangible asset base is heavily compromised by $79.95B in total debt. Physical assets include a 1 million sq ft headquarters in Woonsocket and a 1.7 million sq ft Aetna complex in Hartford, but these provide little solace given the massive liability stack.CVS competes in a destructive pricing environment against Walgreens Boots Alliance (WBA), Elevance Health (ELV), and Cardinal Health (CAH). While CVS holds a 27.8% retail script share and a 33% PBM market share, it operates as a commodity price-taker. Gross margins of 13.8% trail the peer median of 16.0%, and the industry is facing a regulatory reset that threatens the traditional PBM spread-based model.The historical narrative is one of rapid decline and distress. What went wrong was a combination of over-leveraged acquisitions (Aetna, Oak Street, Signify) and a failure to anticipate rising medical cost trends in Medicare Advantage. Financial trends demonstrate severe deterioration, with operating income collapsing 45% to $4.7B in FY2025. Strategic missteps discussed by management include the over-aggressive expansion of Oak Street Health clinics, which led to the $5.7B impairment. The critical negative turning point was the October 2024 departure of CEO Karen Lynch amid financial challenges in the Aetna segment, leading to the appointment of J. David Joyner and the forced inclusion of activist Larry Robbins (Glenview Capital) on the board.

Business & Situation

<ul><li>Bull Case: Successful execution of the $2B cost-savings program and Aetna margin recovery to historical norms; stabilization of PBM margins through the TrueCost transparency model.</li><li>Bear Case: Persistent Medicare Advantage utilization spikes exceeding premium increases; Federal Trade Commission (FTC) or legislative action permanently impairing PBM profitability; inability to refinance $15.7B in 2026 maturities at favorable rates.</li></ul>The consensus view is that CVS is a 'too big to fail' healthcare utility trading at a distressed multiple, where any sign of margin stabilization will trigger a massive re-rating. This narrative is driven by the company's robust $10.6B in operating cash flow and its dominant market position. However, this ignores the quality of those earnings and the massive debt burden.The industry is facing a 'destructive' phase of the capital cycle. While an aging population increases demand, regulatory rate caps and rising medical utilization are compressing margins across the payer space. CVS is underperforming the sector, with a 3-year alpha of -37.15% versus the market.Our differentiated view is that the market is pricing in a successful turnaround while ignoring the quantifiable asset floor, which is effectively zero. Contrast the operational failure-evidenced by a ROIC of only 1.5%-with the fact that liabilities exceed realizable assets in a liquidation scenario. While activist involvement from Glenview Capital (Larry Robbins) puts a theoretical floor on the valuation by pushing for a strategic review or breakup, the governance friction and Robbins' own recent sales of 1.6M+ shares suggest even insiders and activists are hedging their bets. The activism may prevent 'value drift,' but it cannot easily fix a business model facing a regulatory reset and a 13.5x net debt/EBITDA ratio.We conclude that the risks of a failed turnaround and the lack of downside protection far outweigh the potential upside from a successful margin recovery. The equity is currently priced for perfection in a business that has consistently missed EPS guidance 80% of the time over the last five years.Our analytical edge stems from a forensic analysis of the balance sheet and creditor agreements, giving us higher conviction in the lack of monetizable value in the company's assets. While the equity market focuses on adjusted EPS, we focus on the -$35.8B tangible book value and the 1.7x interest coverage, which signal a company with very little margin for error.

Core Thesis

CEO J. David Joyner is a 37-year internal veteran who previously led the Pharmacy Services segment. While he drove that segment to record revenues, he lacks a verifiable track record of executing a complex, multi-segment turnaround. His appointment occurred during a period of extreme distress, and he is currently managing a contested transition where activist Glenview Capital is pushing for more aggressive restructuring than the current plan.Capital allocation skill is rated as 'Weak.' Management deployed $7.9B in buybacks and $3.8B in dividends in FY2025 despite 15.3x net leverage, a move that destroyed value given the stock's subsequent underperformance and the company's precarious liquidity position.Management's credibility is strained; while they candidly disclosed the $5.7B impairment, they continue to claim pricing power despite a 1.1 percentage point drop in operating margins.<ul><li>Board Independence: 100% (5 of 5 listed independents)</li><li>Chairman/CEO Roles: Combined (J. David Joyner)</li><li>Chairman Tenure: Since Jan 2026</li><li>Insider Ownership: 1.26%</li><li>Shareholder Rights: 15% Special Meeting Threshold, No Poison Pill</li></ul>The governance environment is currently a 'Battleground.' We outline the Governance Outcome Tree: 1. Status Quo: Joyner executes the $2B plan, leading to modest recovery (Base Case); 2. Compromise: Glenview gains more influence, potentially forcing a spin-off of Aetna or the PBM; 3. Reset: Continued misses lead to a full board overhaul or a forced strategic sale. Given that insiders sold $254.6M in stock over the last 12 months, management's own conviction in the 'Status Quo' appears dangerously low.

Leadership & Governance

Although the theoretical Low Case Net Liquidation Value (NLV) is $0.00, the stock currently trades at $80.57. To provide a conservative downside bound, we anchor the floor to the Bear Case DCF value of $0.00, reflecting the risk of a failed turnaround and the fact that liabilities exceed adjusted tangible assets.Assumes moderate execution on $2B cost savings and Aetna recovery, with operating margins reaching 3.0% by Year 3. Implied value: $123.57.Accelerated $2B savings and Aetna MBR falling below 90% drive 10% revenue growth and 4% margins. Blue-Sky Potential: $161.87.Aetna margin failure and PBM regulatory caps trigger a covenant breach and liquidity crisis. In this distressed framework, the equity value is $0.00 as the company lacks sufficient runway to survive a failed restructuring without massive dilution or restructuring.

Valuation Context

<ul><li>Aetna Medical Benefit Ratio (MBR) falling below 91% in Q3 2026. This would validate the margin-recovery narrative and suggest that pricing actions are finally offsetting utilization trends.</li><li>Successful divestiture of non-core assets (e.g., Oak Street Health or Signify Health). Selling these assets at a premium would provide a crucial bridge to safety and allow for debt paydown.</li><li>CVS is at a critical juncture following the appointment of J. David Joyner and the entry of Glenview Capital, with the market awaiting proof that the $2B cost-savings plan can offset structural headwinds in Medicare Advantage.</li></ul>CVS is at a critical juncture following the appointment of J. David Joyner and the entry of Glenview Capital, with the market awaiting proof that the $2B cost-savings plan can offset structural headwinds in Medicare Advantage.

Catalyst Path & Context

<ul><li>Existential Liquidity and Solvency Risk. The company faces a 'race against time' to restore operating income before its $15.7B in 2026 debt maturities become unrefinancable at sustainable rates. Net debt/EBITDA of 13.5x and interest coverage of 1.7x provide almost no margin for error.</li><li>Regulatory Impairment of PBM Profitability. An FTC lawsuit regarding insulin pricing and potential federal legislation could permanently cap PBM margins. The Health Services segment, which includes the PBM, saw a $5.7B goodwill impairment in 2025.</li><li>The governance environment is currently a 'Battleground.' We outline the Governance Outcome Tree: 1. Status Quo: Joyner executes the $2B plan, leading to modest recovery (Base Case); 2. Compromise: Glenview gains more influence, potentially forcing a spin-off of Aetna or the PBM; 3. Reset: Continued misses lead to a full board overhaul or a forced strategic sale. Given that insiders sold $254.6M in stock over the... Risk monitor: Current price $80.57 vs fair value $65.36, expected return -18.9%.</li></ul>

Primary Risks

<ul><li>Entry Target: No new entries: recommendation is Sell.</li><li>Stop Loss: No stop-loss needed because recommendation is Sell (no position).</li><li>Position Size: Position size is None under current recommendation and risk constraints.</li><li>Time Horizon: N/A for a Sell recommendation.</li></ul><ul><li>Management's 2026 guidance assumes a steeper quarterly MBR increase, making any outperformance a significant positive signal.</li><li>Activist Glenview Capital is reportedly pushing for a strategic review of the company's integrated model.</li><li>Net debt/EBITDA of 13.5x and interest coverage of 1.7x provide almost no margin for error.</li></ul>A definitive liquidity event, such as a failure to refinance upcoming 2026 maturities or a covenant breach triggered by further Aetna margin deterioration. Also require valuation reliability to improve before re-entering.

Actionable Parameters & Monitoring

CVS appears overvalued (fair value $65.36 vs current $80.57, expected return -18.9%). Recommendation: Sell; do not allocate until valuation and risk profile reset.

Final Conclusion

Structural margin erosion and excessive leverage

Driver

Failure to meet Aetna margin recovery targets or adverse PBM regulatory resets

Catalyst

Protection

Successful execution of the $2B cost-savings program and Aetna margin recovery to historical norms; stabilization of PBM margins through the TrueCost transparency model.

Bull Case

Persistent Medicare Advantage utilization spikes exceeding premium increases; Federal Trade Commission (FTC) or legislative action permanently impairing PBM profitability; inability to refinance $15.7B in 2026 maturities at favorable rates.

Bear Case

Situation: Current price is $80.57 versus fair value $65.36 (-18.9% expected return), and valuation confidence is partial. Debate: Bull case depends on Aetna Medical Benefit Ratio (MBR) falling below 91% in Q3 2026. Bear case centers on Existential Liquidity and Solvency Risk. Conclusion: Recommendation is Sell with no position, pending a materially better risk/reward setup.

The strategy evolved from aggressive cost-cutting and Aetna restructuring in FY2024 to a focus on integrated, transparent healthcare delivery and profitability in FY2025, marked by exits from non-core businesses and emphasis on enterprise connectivity.

Method	Implied Value	Weight	Weighted Value
DCF	$110.34	35%	$38.62
Comps	$42.88	55%	$23.58
Historicals	$31.54	10%	$3.15
Total Weighted			$65.36

CVS

Company Overview

Price History